Abstract
Purpose. The objective of this study was to examine the metabolism and disposition of the HIV protease inhibitor lopinavir in humans and animal models.
Methods. The plasma protein binding of [14C]lopinavir was examined in vitro via equilibrium dialysis technique. The tissue distribution of radioactivity was examined in rats dosed with [14C]lopinavir in combination with ritonavir. The metabolism and disposition of [14C]lopinavir was examined in rats, dogs, and humans given alone (in rats only) or in combination with ritonavir.
Results. The plasma protein binding of lopinavir was high in all species (97.4-99.7% in human plasma), with a concentration-dependent decrease in binding. Radioactivity was extensively distributed into tissues, except brain, in rats. On oral dosing to rats, ritonavir was found to increase the exposure of lopinavir-derived radioactivity 13-fold. Radioactivity was primarily cleared via the hepato-biliary route in all species (>82% of radioactive dose excreted via fecal route), with urinary route of elimination being significant only in humans (10.4% of radioactive dose). Oxidative metabolites were the predominant components of excreted radioactivity. The predominant site of metabolism was found to be the carbon-4 of the cyclic urea moiety, with subsequent secondary metabolism occurring on the diphenyl core moiety. In all the three species examined, the primary component of plasma radioactivity was unchanged lopinavir (>88%) with small amounts of oxidative metabolites.
Conclusions. Lopinavir was subject to extensive metabolism in vivo. Co-administered ritonavir markedly enhanced the pharmacokinetics of lopinavir-derived radioactivity in rats, probably due to inhibition of presystemic and systemic metabolism, leading to an increased exposure to this potent HIV protease inhibitor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
N. A. Roberts, J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krhn, R. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361 (1990).
J. P. Vacca, B. Borsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, L.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. L-735-524: An orally bioavailable human immunodeficiency virus type I protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100 (1994).
S. A. Danner, A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzalez, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. Gill Aguado, and J. C. C. Garcia de Lomas Delgrado Jr. Borieffs, A. Hsu, J. Valdes, C. A. B. Boucher, and D. A. Cooper. A shortterm study of the safety, pharmacokinetics and efficacy of RVR, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533 (1995).
D. J. Kempf, K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fina, C. H. Park, X.-P. Kong, N. E. Wieburg, A. Salvidar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488 (1995).
A. K. Patick, H. Mo, M. Markowitz, T. Appel, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297 (1996).
J. P. Vacca and J. H. Condra. Clinically effective HIV-1 protease inhibitors. Drug Discov. Today 2:261-272 (1997).
A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavsky, T. P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766 (1996).
H. Sham, D. J. Kempf, A. Molla, K. C. Marsh, G. N. Kumar, C. M. Chen, W. Kati, K. Stewart, R. Lal, A. Hsu, D. Betebenner, M. Korneyeva, S. Vasavanonda, E. McDonald, A. Saldivar, N. Wideburg, X. Chen, P. Niu, C. Park, V. Jayanti, B. Grabowski, G. R. Granneman, E. Sun, A. J. Japour, J. Plattner, and D. Norbeck. LVR, a highly potent inhibitor of the human immunodeficiency virus protease. Anitmicrob. Agents Chemother. 42:3218-3234 (1998).
K. Marsh, E. McDonald, H. Sham, D. Kempf, and D. Norbeck. Enhancement of LVR pharmacokinetics when administered in combination with RVR. Proceedings of 4th Conference on Retroviruses and Opportunistic Infections, January 1997, Abstract 210 (1997).
G. N. Kumar, A. D. Rodrigues, A. M. Buko, and J. F. Denissen. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431 (1996).
G. N. Kumar, J. Dykstra, E. M. Roberts, V. Jayanti, D. Hickman, J. Uchic, Y. Yao, B. Surber, S. Thomas, and G. R. Granneman. Potent inhibition of the cytochrome P450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir–a positive drug-drug interaction. Drug Metab. Dispos. 27:902-908 (1999).
R. A. Lal, A. Hsu, P. Chen, S. Dennis, T. El-Shourbagy, C. Locke, W. Lam, A. Japour, J. Leonard, G. R. Granneman, and E. Sun. Single dose pharmacokinetics of LVR in combination with ritonavir. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1997, Abstract Number I-194 (1997).
M. Hurst and D. Faulds. Lopinavir. Drugs 60:1371-1379 (2000).
J. L. Miller. FDA approves new protease inhibitor for HIV infection. Am. J. Health Syst. Pharm. 57:1942 (2000).
G. N. Kumar, V. Jayanti, R. D. Lee, D. N. Whittern, J. Uchic, S. Thomas, P. Johnson, B. Grabowski, H. Sham, D. Betebenner, D. J. Kempf, and J. F. Denissen. In vitro metabolism of the HIV-1 protease inhibitor LVR: species comparison and metabolite identification. Drug Metab. Dispos. 27:86-91 (1999).
R. A. Lal, A. Hsu, G. R. Granneman, T. El-Shourbagy, M. Johnson, W. Lam, L. Manning, A. Japour, and E. Sun. Multiple dose safety, tolerability, and pharmacokinetics of LVR in combination with ritonavir. Proceedings of 5th Conference on Retroviruses and Opportunistic Infections, February 1998, Abstract Number 647 (1998).
G. Pantaleo, C. Grazaiosi, J. F. Damarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358 (1993).
J. K. Ladzins, J. Mestan, G. Goutte, M. R. Walker, G. Bold, H. G. Capraro, and T. Klimkait. In vitro effect of α1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755. A comparative study with other relevant HIV protease inhibitors. J. Infect. Dis. 175:1063-1070 (1997).
A. Molla, S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262 (1998).
M. E. Fitzsimmonsm and J. M. Collins. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:256-266 (1997).
M. Chiba, M. Hensleigh, and J. H. Lin. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: major role of CYP3A. Biochem. Pharmacol. 53:1187-1195 (1997).
D. J. Kempf, K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agent Chemother. 41:654-660 (1997).
A. Hsu, G. R. Granneman, G. Cao, L. Carrothers, and T. El Shourbagy. P. Baroldi P. K. Erdman, F. Brown, E. Sun, and J. M. Leonard. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors. Clin. Pharmacol. Ther. 63:453-464 (1998).
A. Hsu, G. R. Granneman, G. Cao, L. Carrothers, A. Japour, T. El-Shourbagy, S. Dennis, J. Berg, K. Erdman, J. M. Leonard, and E. Sun. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. 42:2784-2791 (1998).
C. Merry, M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tija, S. E. Gibbons, A. M. Breckenridge, and D. J. Back. Saquinavir pharmacokinetics alone or in combination with RVR in HIV-infected patients. AIDS 11:F29-F33 (1997).
J. F. Denissen, B. A. Grabowski, M. A. Johnson, A. M. Buko, D. J. Kempf, S. B. Thomas, and B. W. Surber. Metabolism and Disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab. Dispos. 25:489-501 (1997).
H. L. Sham, D. A. Betebenner, T. Herrin, G. Kumar, A. Saldivar, S. Vasavanonda, A. Molla, D. J. Kempf, J. J. Plattner, and D. W. Norbeck. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Biorg. Med. Chem. Lett. 11:1351-1353 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kumar, G.N., Jayanti, V.K., Johnson, M.K. et al. Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans. Pharm Res 21, 1622–1630 (2004). https://doi.org/10.1023/B:PHAM.0000041457.64638.8d
Issue Date:
DOI: https://doi.org/10.1023/B:PHAM.0000041457.64638.8d